Project Details
Description
A Phase 2, Open-label Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants with PSMA PET-Positive Castration-Resistant Prostate Cancer
| Status | Finished |
|---|---|
| Effective start/end date | 7/3/24 → 7/2/25 |
Funding
- CONVERGENT THERAPEUTICS
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.